Risk factors for massive postoperative bleeding after orthotopic heart transplantation: a retrospective cohort study Authors: Daryna Maruniak, Serhii Sudakevych, Havrylo Kovtun, Anna Melnyk, Borys Todurov, Stepan Maruniak Published: 2026 ABSTRACT AbstractBackgroundOrthotopic heart transplantation (OHT) remains the gold standard for patients with end-stage heart failure; however, postoperative bleeding is a frequent and clinically significant complication associated with increased morbidity and transfusion requirements. Data on predictors of massive bleeding in this population remain limited, particularly regarding the role of viscoelastic testing.MethodsWe conducted a single-center retrospective cohort study including 75 adult patients who underwent OHT between 2019 and 2025. Patients with incomplete data or without preoperative viscoelastic testing (ClotPro) were excluded. The primary endpoint was massive postoperative bleeding defined as ≥BARC III. Secondary endpoints included transfusion requirements, reoperation for bleeding, and postoperative blood loss. Univariate and multivariable logistic regression analyses were performed to identify independent predictors. Receiver operating characteristic (ROC) analysis was used to assess discriminative performance. This study was conducted in accordance with the principles of the Helsinki Declaration and the Istanbul Declaration. No organs were procured from prisoners or from individuals subjected to coercion or financial incentives.ResultsMassive postoperative bleeding occurred in 31 patients (41.3%). Transfusion requirements were high, with red blood cells administered in 69.3%, plasma in 90.7%, and cryoprecipitate in 34.7% of patients. Reoperation for bleeding was required in 16.0% of cases. In univariate analysis, ECMO support, lower platelet count, lower fibrinogen, elevated INR, lower EX-test MCF, higher TPA-test ML, and longer cardiopulmonary bypass duration were associated with bleeding. In multivariable analysis, only EX-test MCF remained an independent predictor (OR 0.91 per 1 mm increase; 95% CI 0.85–0.98; p = 0.011).ConclusionsMassive bleeding after OHT is common and associated with significant transfusion burden. Reduced EX-test MCF is an independent predictor of bleeding and may serve as a valuable tool for early risk stratification and personalized hemostatic management in heart transplant recipients.Keywords: Orthotopic heart transplantation, Postoperative bleeding, Transfusion requirements, Coagulopathy, ClotPro, Maximum clot firmness, EX-test MCF, Extracorporeal membrane oxygenation, Cardiopulmonary bypass Introduction Orthotopic heart transplantation remains the treatment of choice for patients with end-stage heart failure; however, the early postoperative period in this population is frequently complicated by hemorrhagic events that significantly affect the clinical course, transfusion requirements, the need for re-exploration, and overall outcomes [1]. In contemporary cardiac surgery, excessive bleeding and transfusion dependency are considered not only markers of disease severity but also independent predictors of adverse prognosis [2, 3]. The risk of bleeding after heart transplantation is particularly high due to the interplay of multiple pathophysiological mechanisms. These include baseline hemostatic abnormalities in patients with end-stage heart failure, prior anticoagulant and/or antiplatelet therapy, prolonged use of mechanical circulatory support, hemodilution, the effects of cardiopulmonary bypass, systemic inflammatory response, and activation of fibrinolysis [4]. Veno-arterial ECMO as a bridge to transplantation is of particular importance: its use is increasing, but it is associated with a higher incidence of post-transplant morbidity, and ECMO-related coagulopathy includes platelet dysfunction, deficiency or consumption of coagulation factors, and impaired fibrinolysis [5, 6]. Conventional coagulation tests, such as prothrombin time, activated partial thromboplastin time, and international normalized ratio, have limited ability to predict clinically significant bleeding in cardiac surgery, as they reflect only some aspects of hemostasis and do not capture the overall process of clot formation and stabilization [7]. In contrast, contemporary patient blood management guidelines in cardiac surgery emphasize the role of point-of-care viscoelastic testing as a tool for bleeding risk assessment and individualized hemostatic therapy [8]. Viscoelastic methods, including thromboelastography (TEG), rotational thromboelastometry (ROTEM), and ClotPro, allow real-time assessment of clot initiation, clot strength, and fibrinolysis [9]. Clinical studies and meta-analyses in cardiac surgery have demonstrated that viscoelastic-guided algorithms are associated with reduced use of blood components, particularly plasma, platelets, and cryoprecipitate [10]. Specifically, in patients undergoing orthotopic heart transplantation or LVAD implantation, the implementation of TEG-guided algorithms has also been associated with reduced non–red blood cell transfusion requirements [11]. However, data on predictors of massive postoperative bleeding specifically after heart transplantation remain limited, and the role of individual viscoelastic parameters in risk stratification in this population is insufficiently explored [12]. Particular interest is directed toward parameters reflecting clot quality and stability, including the contribution of fibrinogen and maximum clot firmness, as previous studies in cardiac surgery have demonstrated associations between fibrinogen levels, thromboelastographic parameters, and postoperative blood loss. Therefore, the aim of this study was to identify predictors of massive postoperative bleeding following orthotopic heart transplantation, with particular emphasis on preoperative laboratory and viscoelastic parameters. Materials and methods Study design This study was conducted as a single-center retrospective cohort analysis at the Heart Institute of the Ministry of Health of Ukraine. Consecutive adult patients who underwent orthotopic heart transplantation between 2019 and 2025 were included. This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and the Istanbul Declaration on organ trafficking and transplant tourism. All donor organs were obtained in compliance with national and international regulations. No organs were procured from prisoners or from individuals subjected to coercion or financial incentives. The study protocol was approved by the Ethics Committee of the Shupyk National Healthcare University of Ukraine. Due to the retrospective nature of the study, the requirement for informed consent was waived. All data were anonymized prior to analysis to ensure patient confidentiality. Inclusion and exclusion criteria Patients with complete clinical, laboratory, and perioperative data, including thromboelastography (ClotPro) results, were included in the analysis. Exclusion criteria were: use of postoperative extracorporeal membrane oxygenation (ECMO), absence of thromboelastography data, and incomplete clinical or perioperative records. Data collection Demographic, clinical, laboratory, and intraoperative variables were analyzed. Laboratory assessment included standard coagulation parameters (international normalized ratio [INR], activated partial thromboplastin time [aPTT], prothrombin time, fibrinogen, and D-dimer), as well as viscoelastic testing using the ClotPro system (enicor GmbH, Munich, Germany), including EX-test, IN-test, FIB-test, and TPA-test. Viscoelastic testing with ClotPro was performed preoperatively before orthotopic heart transplantation in selected patients considered at increased risk of coagulation disorders or perioperative bleeding. The main indications for preoperative testing included advanced heart failure with suspected baseline coagulopathy, mechanical circulatory support, ongoing anticoagulation therapy, liver dysfunction, previous cardiac surgery, abnormal conventional coagulation tests, thrombocytopenia, or a history of clinically significant bleeding. Intraoperative parameters included ischemic time, cardiopulmonary bypass duration, aortic cross-clamp time, transfusion requirements, use of coagulation factor concentrates, autotransfusion, and activated clotting time (ACT) dynamics. Transfusion protocols Red blood cell transfusion was performed at hemoglobin levels < 80 g/L, or < 90 g/L in patients with hemodynamic instability or signs of tissue hypoxia. Hemodynamic instability was defined as persistent hypotension requiring escalating vasopressor or inotropic support despite adequate volume resuscitation. Signs of tissue hypoxia included elevated serum lactate levels, reduced central venous oxygen saturation (ScvO₂), metabolic acidosis, and clinical evidence of end-organ hypoperfusion such as oliguria or impaired peripheral perfusion. Fresh frozen plasma was administered in the presence of clinically significant bleeding with INR > 1.5 or aPTT > 1.5 times the normal value. Fibrinogen deficiency was corrected using cryoprecipitate or fibrinogen concentrate at fibrinogen levels < 1.5–2.0 g/L or reduced FIB-test maximum clot firmness (MCF < 10–12 mm). Prothrombin complex concentrates was considered in cases of ongoing clinically significant bleeding after exclusion of surgical bleeding and correction of fibrinogen deficiency (FIBTEM A5 < 10 mm or plasma fibrinogen < 1.5–2.0 g/L). Administration was guided by both conventional coagulation tests and viscoelastic parameters, particularly prolonged clotting time on ClotPro assays (EX-test CT > 80–100 s and/or IN-test CT > 240 s), together with INR > 1.5. PCC was administered at doses of 15–25 IU/kg depending on patient body weight, severity of bleeding, and coagulation abnormalities. Recombinant activated factor VII (eptacog alfa) was used only as rescue therapy for refractory, life-threatening bleeding after exclusion of a surgical source of bleeding and after correction of major reversible coagulation abnormalities, including fibrinogen deficiency, thrombocytopenia, hypothermia, acidosis, and hypocalcemia. It was administered as the final pharmacological step of the institutional bleeding management algorithm, after transfusion of blood components and coagulation factor replacement, including fibrinogen concentrate/cryoprecipitate, platelets, fresh frozen plasma, and/or PCC when indicated. The dose was 45–90 µg/kg as a single intravenous bolus, with repeat administration considered only in persistent uncontrolled bleeding. Clinical endpoints The primary endpoint was the occurrence of massive postoperative bleeding, defined as Bleeding Academic Research Consortium (BARC) type ≥ 3 bleeding. Although originally developed for cardiovascular interventional studies, BARC criteria are increasingly used in cardiac surgery and critically ill populations as a standardized definition of clinically significant bleeding. Secondary endpoints included transfusion requirements, need for surgical re-exploration due to bleeding, and total postoperative blood loss. Statistical analysis Continuous variables were presented as mean ± standard deviation or median (interquartile range, IQR), while categorical variables were expressed as counts and percentages. Univariable and multivariable logistic regression analyses were performed to identify predictors of massive bleeding, with results reported as odds ratios (OR) and 95% confidence intervals (CI). A p-value < 0.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 23.0 (IBM Corp., Armonk, NY, USA). Results Between 2019 and 2025, a total of 172 orthotopic heart transplantations were performed at the Heart Institute of the Ministry of Health of Ukraine. A total of 97 patients were excluded from the analysis, including those who required postoperative extracorporeal membrane oxygenation (n = 14), those without available thromboelastography (TEG) data (n = 76), those with incomplete clinical or perioperative data (n = 7). Thus, a total of 75 patients were included in the final analysis (Fig. 1). Study flowchart Detailed baseline characteristics of the study population are presented in Table 1. The mean age was 50.6 ± 11.9 years, and the majority of patients were male (77.3%). The most common underlying etiology of heart failure was dilated cardiomyopathy. Prior to transplantation, mechanical circulatory support was used in 49.3% of cases, including veno-arterial ECMO in 41.3% of patients. Table 1Baseline characteristics of recipientsVariablesPatients (n = 75)Age, years50.6 ± 11.9Male sex, n (%)58 (77.3%)BMI, kg/m²27.2 ± 4.6Etiology of heart failure, n (%)– Dilated cardiomyopathy36 (48.0%)– Hypertrophic cardiomyopathy6 (8.0%)– Ischemic cardiomyopathy25 (33.3%)– Other8 (10.7%)Diabetes mellitus, n (%)14 (18.7%)Atrial fibrillation, n (%)21 (28.0%)Pacemaker, n (%)9 (12.0%)Prior cardiac surgery, n (%)18 (24.0%)Left ventricular ejection fraction, %22.8 ± 6.52LV end-diastolic volume, mL234.4 ± 52.1Pulmonary artery pressure, mmHg47.4 ± 11.6NT-proBNP, pg/mL8252 (4162–14841)Prior anticoagulant therapy, n (%)49 (65.3%)Prior antiplatelet therapy, n (%)31 (41.3%)Blood group, n (%)– O (I)30 (40.0%)– A (II)26 (34.7%)– B (III)12 (16.0%)– AB (IV)7 (9.3%)Mechanical circulatory support, n (%)– ECMO44 (58.7%)– VAD6 (8.0%)BMI – body mass index; HF – heart failure; LVEF – left ventricular ejection fraction; LVEDV – left ventricular end-diastolic volume; NT-proBNP – N-terminal pro–B-type natriuretic peptide; ECMO – extracorporeal membrane oxygenation; VAD – ventricular assist device Baseline characteristics of recipients BMI – body mass index; HF – heart failure; LVEF – left ventricular ejection fraction; LVEDV – left ventricular end-diastolic volume; NT-proBNP – N-terminal pro–B-type natriuretic peptide; ECMO – extracorporeal membrane oxygenation; VAD – ventricular assist device In the studied cohort, signs of moderate coagulopathy were observed, including decreased platelet count and fibrinogen levels in the presence of elevated INR, aPTT, and D-dimer levels (Table 2). Table 2Baseline complete blood count and coagulation profileVariablesPatients (n = 75)Red blood cells, ×10¹²/L4.17 ± 0.63Hemoglobin, g/L121.0 ± 17.0Platelets, ×10⁹/L156.0 ± 58.0INR1.62 ± 0.19aPTT, s40.0 ± 12.0Prothrombin time, s16.4 ± 3.6Fibrinogen, g/L2.3 ± 0.7D-dimer, mg/L2.6 (1.3–5.4)INR – international normalized ratio; aPTT – activated partial thromboplastin time Baseline complete blood count and coagulation profile INR – international normalized ratio; aPTT – activated partial thromboplastin time Additionally, ClotPro analysis demonstrated pronounced disturbances of the hemostatic system in patients prior to orthotopic heart transplantation, reflecting both a hypocoagulable state and increased fibrinolytic activity (Table 3). Table 3ClotPro test results before heart transplantsVariablesPatients (n = 75)EX-test: CT, s88,3 ± 24,6EX-test: MCF, mm51,2 ± 9,21EX-test: ML, %10,5 ± 6,07FIB-test: MCF, mm10,5 ± 4,21IN-test: CT, s215,7 ± 65,2IN-test: MCF, mm49,1 ± 9,63TPA test: MCF, mm34,6 ± 11,0TPA test: LT, s2650,2 ± 720,6TPA test: ML, %19,1 ± 9,6EX-test – extrinsically activated test; IN-test – intrinsically activated test; FIB-test – fibrin-based test reflecting fibrinogen contribution to clot strength; TPA-test – tissue plasminogen activator–induced fibrinolysis test; CT – clotting time; MCF – maximum clot firmness; ML – maximum lysis; LT – lysis time ClotPro test results before heart transplants EX-test – extrinsically activated test; IN-test – intrinsically activated test; FIB-test – fibrin-based test reflecting fibrinogen contribution to clot strength; TPA-test – tissue plasminogen activator–induced fibrinolysis test; CT – clotting time; MCF – maximum clot firmness; ML – maximum lysis; LT – lysis time In particular, EX-test parameters demonstrated a moderate prolongation of clotting time (CT 88.3 ± 24.6 s), which may reflect coagulation factor deficiency or the effect of prior anticoagulant therapy. A reduced maximum clot firmness (MCF 51.2 ± 9.21 mm) indicates impaired formation of a stable clot, while an increased maximum lysis (ML 10.5 ± 6.07%) suggests activation of fibrinolysis. FIB-test results (MCF 10.5 ± 4.21 mm) demonstrate a reduced contribution of fibrinogen to clot formation, which represents a critical factor in the development of postoperative bleeding. Similarly, IN-test showed prolonged coagulation time (CT 215.7 ± 65.2 s) and decreased clot strength (MCF 49.1 ± 9.63 mm), further confirming the presence of systemic coagulopathy. TPA-test parameters indicate significant activation of the fibrinolytic system: relatively reduced MCF (34.6 ± 11.0 mm), shortened lysis time (LT 2650.2 ± 720.6 s), and elevated ML (19.1 ± 9.6%) are consistent with a tendency toward hyperfibrinolysis. Regarding intraoperative parameters, the mean ischemic time was 186.4 ± 41.2 min, cardiopulmonary bypass duration was 150.2 ± 35.6 min, and aortic cross-clamp time was 93.1 ± 24.3 min (Table 4). Table 4Intraoperative and early postoperative parametersVariablesAll patients (n = 75)Ischemic time, min186.4 ± 41.2Cardiopulmonary bypass time, min150.2 ± 35.6Aortic cross-clamp time, min93.1 ± 24.3 Blood products and coagulation factor use Red blood cell transfusion, n (%)52 (69.3%)Plasma transfusion, n (%)68 (90.7%)Cryoprecipitate, n (%)26 (34.7%)Prothrombin complex concentrates (factors II, VII, IX, X), n (%)38 (50.7%)Eptacog alfa, n (%)7 (9.34%) Autotransfusion use – Frequency, n (%)49 (65.3%)– Intraoperative washed RBC volume, mL620.0 (350.0–1100.0)– Washed RBC volume on postoperative day 1, mL480.0 (250.0–850.0) ACT dynamics Baseline ACT, s142.3 ± 28.4ACT during heparinization, s472.5 ± 65.1ACT after protamine, s128.1 ± 31.6Additional protamine use, n (%)18 (24.0%)Re-exploration for bleeding, n (%)12 (16.0%)Postoperative bleeding ≥ BARC III, n (%)31 (41.3%)RBC – red blood cells; CPB – cardiopulmonary bypass; ACT – activated clotting time Intraoperative and early postoperative parameters RBC – red blood cells; CPB – cardiopulmonary bypass; ACT – activated clotting time Autotransfusion was used in 65.3% of patients, with a median volume of returned red blood cells of 620.0 (350.0–1100.0) mL intraoperatively and 480.0 (250.0–850.0) mL during the first postoperative day. Additional protamine administration was required in 24.0% of patients. In the early postoperative period, re-exploration for bleeding was necessary in 16.0% of cases. Massive postoperative bleeding (≥ BARC III) occurred in 41.3% of patients. In univariable analysis, the use of ECMO, lower platelet and fibrinogen levels, elevated INR, reduced EX-test MCF, increased TPA-test ML, and longer cardiopulmonary bypass duration were associated with an increased risk of massive postoperative bleeding (Table 5). Table 5Logistic regression analysis of predictors of massive bleeding after orthotopic heart transplantationVariablesUnivariate OR (95% CI) p Multivariable OR (95% CI) p ECMO, yes/no3.42 (1.21–9.68)0.0212.11 (0.78–5.71)0.14Platelets (per 10⁹/L)0.98 (0.97–0.99)0.0060.99 (0.97–1.00)0.09Fibrinogen, g/L0.52 (0.31–0.88)0.0150.71 (0.43–1.18)0.19INR2.11 (1.08–4.12)0.0281.58 (0.79–3.18)0.20EX-test MCF (per 1 mm)0.90 (0.84–0.96)0.0040.91 (0.85–0.98)0.011TPA-test ML1.09 (1.03–1.16)0.0031.04 (0.98–1.10)0.16CPB (per 10 min)1.17 (1.03–1.33)0.0141.09 (0.97–1.23)0.15Prior cardiac surgery, yes/no2.63 (0.95–7.28)0.062––ECMO – extracorporeal membrane oxygenation; INR – international normalized ratio; EX-test MCF – maximum clot firmness in the extrinsic test; TPA-test ML – maximum clot lysis in the tissue plasminogen activator test; CPB – cardiopulmonary bypass Logistic regression analysis of predictors of massive bleeding after orthotopic heart transplantation ECMO – extracorporeal membrane oxygenation; INR – international normalized ratio; EX-test MCF – maximum clot firmness in the extrinsic test; TPA-test ML – maximum clot lysis in the tissue plasminogen activator test; CPB – cardiopulmonary bypass In multivariable logistic regression analysis, only lower EX-test MCF remained independently associated with the development of massive bleeding (OR 0.91 per 1 mm increase; 95% CI 0.85–0.98; p = 0.011). Discussion In this study, we demonstrated that massive postoperative bleeding (≥ BARC III) after orthotopic heart transplantation occurred in 41.3% of patients, which is consistent with contemporary data in patients receiving mechanical circulatory support, where the incidence of clinically significant bleeding reaches 40–50% [13]. The pathophysiology of coagulopathy in heart transplant recipients is complex and multifactorial. It involves a combination of preoperative hemostatic disturbances related to end-stage heart failure and the use of mechanical circulatory support, intraoperative factors (cardiopulmonary bypass, hemodilution, hypothermia), and postoperative activation of the inflammatory response [14]. Our findings support the multifactorial nature of coagulopathy in this population. Previous studies have shown that patients supported with ECMO develop a hypocoagulable state characterized by platelet dysfunction, reduced fibrinogen levels, and impaired clot formation [15]. Furthermore, extracorporeal support has been associated with reduced clot firmness (MCF) and prolonged clotting time, both of which correlate with an increased risk of bleeding [16]. In our study, only EX-test MCF remained an independent predictor of massive bleeding in multivariable analysis. This finding has a strong pathophysiological basis, as MCF represents an integrative parameter reflecting the interaction between platelets, fibrinogen, and coagulation factors. Similar observations have been reported in patients with mechanical circulatory support, where reduced MCF was significantly associated with bleeding complications [17]. In addition, ROTEM-based studies have demonstrated that lower EXTEM MCF values correlate with increased blood loss and a higher need for surgical re-exploration [18]. Interestingly, conventional coagulation parameters (INR, aPTT, fibrinogen) did not retain independent predictive value. This aligns with the current understanding that standard laboratory tests assess isolated components of hemostasis and fail to capture its dynamic and integrative nature [19]. In contrast, viscoelastic methods provide real-time, comprehensive assessment of clot initiation, propagation, stabilization, and lysis [20, 21]. An additional important finding is the activation of the fibrinolytic system, reflected by increased ML and shortened LT in the TPA-test. This is consistent with current evidence on ECMO-associated hyperfibrinolysis and highlights the need for early identification and targeted correction of fibrinolytic disturbances [22]. From a clinical perspective, our results support the implementation of viscoelastic-guided transfusion algorithms. Randomized studies in cardiac surgery have shown that ROTEM- and TEG-guided strategies can reduce blood loss and transfusion requirements, particularly in patients at high risk of coagulopathy [23]. Thus, our study expands current knowledge on the role of viscoelastic parameters in predicting bleeding after heart transplantation and confirms that EX-test MCF is a clinically relevant integrative marker of hemostatic impairment. Its use may represent a key component of personalized hemostatic management strategies in high-risk patients. This study has several limitations that should be considered when interpreting the results. Its retrospective, single-center design limits generalizability and does not allow complete exclusion of residual confounding. The relatively small sample size may reduce statistical power and the precision of effect estimates. An important limitation is the selection bias inherent to the study population, as viscoelastic testing was not routinely performed but rather applied in patients at higher risk of complications, particularly bleeding. This likely resulted in enrichment of the cohort with more severe cases, which may partly explain both the high incidence of massive bleeding and the substantial proportion of patients requiring ECMO support. In addition, not all potentially relevant factors influencing bleeding risk – such as surgical technique, operator experience, and individualized transfusion strategies – were fully accounted for. Therefore, the findings should be interpreted with caution and require validation in larger, prospective, multicenter studies. Conclusions In patients undergoing orthotopic heart transplantation, massive postoperative bleeding (≥ BARC III) occurred in 31 of 75 patients (41.3%) and was associated with a substantial transfusion burden (red blood cells 69.3%, plasma 90.7%, cryoprecipitate 34.7%) and a high rate of surgical re-exploration (16.0%). In multivariable analysis, EX-test MCF emerged as the only independent predictor of massive bleeding (OR 0.91 per 1 mm increase; 95% CI 0.85–0.98; p = 0.011). Acknowledgements Not applicable. Abbreviations Activated clotting time Activated partial thromboplastin time Area under the curve Bleeding Academic Research Consortium Body mass index Confidence interval Cardiopulmonary bypass Clotting time Extracorporeal membrane oxygenation Test–Extrinsically activated test Test–Fibrin–based test International normalized ratio Test–Intrinsically activated test Interquartile range Lysis time Left ventricular assist device Left ventricular ejection fraction Maximum clot firmness Maximum lysis Negative predictive value Orthotopic heart transplantation Odds ratio Positive predictive value Receiver operating characteristic Red blood cells Standard deviation Thromboelastography Test–Tissue plasminogen activator test Author contributions DM contributed to study design, data collection, statistical analysis, and drafting of the manuscript. SS contributed to data collection, interpretation of clinical data, and manuscript revision. HK contributed to data acquisition and analysis. AM contributed to data collection and manuscript preparation. BT contributed to study conception, supervision, and critical revision of the manuscript. SM contributed to study design, interpretation of results, and critical revision of the manuscript. All authors read and approved the final manuscript. Funding The authors declare that no financial support was received for this study. Data availability The data underlying this article will be shared on reasonable request to the corresponding author. Declarations Ethics approval and consent to participate This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and the Istanbul Declaration on organ trafficking and transplant tourism. All donor organs were obtained in compliance with national regulations. No organs were procured from prisoners or from individuals subjected to coercion or financial incentives. The study protocol was approved by the Ethics Committee of the Shupyk National Healthcare University of Ukraine. Written informed consent for publication was waived due to the retrospective nature of the study. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The data underlying this article will be shared on reasonable request to the corresponding author.